Clinical Trial Update: Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies [Phase 1, Phase 2]

View source ↗

Summary

This Clinical Trial Update describes a Phase 1/2 study of the ATR inhibitor peposertib in combination with the PD-L1 inhibitor avelumab and radiation therapy fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Gallbladder Cancer

Drugs mentioned

• Avelumab (avelumab)
• Peposertib (Peposertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING